LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 19, 2005--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that the 30-day waiting period relating to the Company’s Investigational New Drug application for the intravenous formulation of zileuton (zileuton IV) has ended. The Company plans to begin a Phase I/II study of zileuton IV in the United States in the first quarter of 2006. Critical Therapeutics owns worldwide rights to the zileuton franchise, including ZYFLO(R), an FDA-approved oral tablet formulation that the Company is marketing in the United States for the prevention and chronic treatment of asthma in adults and children 12 years of age and older.
